Paradigm Biopharmaceuticals (ASX:PAR) said a study of its lead product, pentosan polysulfate sodium (PPS), in canine osteoarthritis showed sustained reductions in chronic pain and normalization of gait symmetry through 26 weeks, compared with placebo, according to a Wednesday filing with the Australian bourse.

The study assesses the durability and potential disease-modifying effects of a six-week course of PPS in dogs with naturally occurring osteoarthritis of the stifle and/or elbow joints, the filing said.

Following the treatment, magnetic resonance imaging and serum biomarker findings were consistent with slowed cartilage degradation and altered bone and cartilage turnover, the filing said.

The study also provides a compressed analogue of longer-term human outcomes, the filing added.

Shares of the company fell 1% in recent Wednesday trade.